Research map: A mortality model for relapsed or refractory multiple myeloma: emulation of subjective life expectancy criteria from a clinical trial in real-world data

Back to the article

Papers in this map

  1. Regularization Paths for Generalized Linear Models via Coordinate Descent · Jerome H. Friedman · 2010 · 21057 citations · Cited by this paper
  2. Posttransplant lymphoproliferative disorders following hematopoietic stem cell transplantation: a clinicopathological study of a large single-center cohort · 2026 · Related
  3. Multiple imputation using chained equations: Issues and guidance for practice · Ian R. White · 2010 · 10039 citations · Cited by this paper
  4. Simultaneous onset of familial hemophagocytic lymphohistiocytosis and T-cell large granular lymphocytic leukemia in an adult · 2026 · Related
  5. A note on a general definition of the coefficient of determination · N. J. D. Nagelkerke · 1991 · 5812 citations · Cited by this paper
  6. Angioimmunoblastic T-cell lymphoma following Castleman’s disease: diagnostic challenges and literature review · 2026 · Related
  7. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement · Professor Gary S. Collins · 2015 · 2017 citations · Cited by this paper
  8. Single low-dose daratumumab enhances rituximab efficacy for sustained remission in treatment-refractory autoimmune cytopenias · 2026 · Related
  9. On evaluation metrics for medical applications of artificial intelligence · Steven Alexander Hicks · 2022 · 917 citations · Cited by this paper
  10. Analysis of the diagnostic efficacy of hemoglobin capillary electrophoresis for thalassemia in children under 2 years old in Southern Fujian (Minnan) Region, China · 2026 · Related
  11. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients · Monika Martha Engelhardt · 2017 · 279 citations · Cited by this paper
  12. Sea-blue histiocytosis and thrombocytopenia successfully treated with an mTORC1 inhibitor: a case report · 2026 · Related
  13. Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015 · Susan Jin · 2017 · 224 citations · Cited by this paper
  14. 30 years in service, 1996–2026: Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) · 2026 · Related
  15. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma · Naresh Bumma · 2024 · 180 citations · Cited by this paper
  16. Sequential emergence of FLT3-ITD and BCR::ABL1 during disease progression in relapsed acute myeloid leukemia · 2026 · Related
  17. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma · Sundar Jagannath · 2021 · 90 citations · Cited by this paper
  18. A rare case of acute basophilic leukemia transformed from high risk myelodysplastic syndrome · 2026 · Related
  19. A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma · Han-Ying Huang · 2021 · 43 citations · Cited by this paper
  20. Diagnosis and treatment of familial hemophagocytic lymphohistiocytosis with isolated central nervous system involvement: A case report · 2026 · Related
  21. Developing clinical prediction models when adhering to minimum sample size recommendations: The importance of quantifying bootstrap variability in tuning parameters and predictive performance · Glen Philip Martin · 2021 · 38 citations · Cited by this paper
  22. Investigating the effects of ties on measures of concordance · Guofen Yan · 2008 · 22 citations · Cited by this paper
  23. Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma · Roman Hájek · 2019 · 19 citations · Cited by this paper
  24. Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making · Sebastian Gonzalez‐McQuire · 2019 · 15 citations · Cited by this paper
  25. Pleural effusion-based nomogram to predict outcomes in unselected patients with multiple myeloma: a large single center experience · Ziliang Hou · 2021 · 11 citations · Cited by this paper
  26. “Sufficient Life Expectancy”: An Amazing Inclusion Criterion in Cancer Phase II-III Trials · Nicolas Penel · 2009 · 9 citations · Cited by this paper
  27. Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review · Shaji Kunnathu Kumar · 2025 · 9 citations · Cited by this paper
  28. Feasibility of Using Oncology-Specific Electronic Health Record (EHR) Data to Emulate Clinical Trial Eligibility Criteria · Thomas W. Wilson · 2023 · 6 citations · Cited by this paper
  29. Abstracts of ICPE 2023, the 39th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Halifax, Canada, 25–27 August 2023 · Beau, Anna-Belle · 2023 · 6 citations · Cited by this paper
  30. Real-world comparison of daratumumab-based regimens in relapsed/refractory multiple myeloma using health record data · Benjamin Avi Derman · 2024 · 6 citations · Cited by this paper
  31. Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). · Shaji Kunnathu Kumar · 2024 · 6 citations · Cited by this paper
  32. Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting · Walter Bouwmeester · 2019 · 4 citations · Cited by this paper
  33. Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review · Roman Hájek · 2020 · 4 citations · Cited by this paper
  34. Identification of a three-gene-based prognostic model in multiple myeloma using bioinformatics analysis · Ying Pan · 2021 · 4 citations · Cited by this paper
  35. Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma · Shaji Kumar · 2026 · 4 citations · Cited by this paper
  36. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection? · Lena Weiss · 2023 · 2 citations · Cited by this paper
  37. Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States · Shaji Kumar · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)